[go: up one dir, main page]

MA41977A - Imidazopyrazinones utilisées comme inhibiteurs de pde1 - Google Patents

Imidazopyrazinones utilisées comme inhibiteurs de pde1

Info

Publication number
MA41977A
MA41977A MA041977A MA41977A MA41977A MA 41977 A MA41977 A MA 41977A MA 041977 A MA041977 A MA 041977A MA 41977 A MA41977 A MA 41977A MA 41977 A MA41977 A MA 41977A
Authority
MA
Morocco
Prior art keywords
imidazopyrazinones
pde1 inhibitors
pde1
inhibitors
imidazopyrazinones used
Prior art date
Application number
MA041977A
Other languages
English (en)
Other versions
MA41977B1 (fr
Inventor
Mikkel Jessing
Karsten Juhl
Jan Kehler
Morten Langgård
Lars Kyhn Rasmussen
Paulo Jorge Vieira Vital
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MA41977A publication Critical patent/MA41977A/fr
Publication of MA41977B1 publication Critical patent/MA41977B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA41977A 2015-04-30 2016-04-29 Imidazopyrazinones utilisées comme inhibiteurs de pde1 MA41977B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201500261 2015-04-30
DKPA201500666 2015-10-29
DKPA201600202 2016-04-04
EP16720101.1A EP3288944B1 (fr) 2015-04-30 2016-04-29 Imidazopyrazinones utilisées comme inhibiteurs de pde1
PCT/EP2016/059583 WO2016174188A1 (fr) 2015-04-30 2016-04-29 Imidazopyrazinones utilisées comme inhibiteurs de pde1

Publications (2)

Publication Number Publication Date
MA41977A true MA41977A (fr) 2018-07-23
MA41977B1 MA41977B1 (fr) 2019-08-30

Family

ID=55910242

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41977A MA41977B1 (fr) 2015-04-30 2016-04-29 Imidazopyrazinones utilisées comme inhibiteurs de pde1

Country Status (42)

Country Link
US (4) US20160318939A1 (fr)
EP (1) EP3288944B1 (fr)
JP (1) JP6663930B2 (fr)
KR (1) KR102605759B1 (fr)
CN (1) CN107531714B (fr)
AU (1) AU2016256573B2 (fr)
BR (1) BR112017023182B1 (fr)
CA (1) CA2983563A1 (fr)
CL (1) CL2017002719A1 (fr)
CO (1) CO2017010399A2 (fr)
CY (1) CY1121806T1 (fr)
DK (1) DK3288944T3 (fr)
DO (1) DOP2017000254A (fr)
EA (1) EA031946B1 (fr)
EC (1) ECSP17072228A (fr)
ES (1) ES2735422T3 (fr)
GE (1) GEP20207058B (fr)
GT (1) GT201700223A (fr)
HK (1) HK1252098B (fr)
HR (1) HRP20191180T1 (fr)
HU (1) HUE044244T2 (fr)
IL (1) IL255316B (fr)
JO (1) JO3627B1 (fr)
LT (1) LT3288944T (fr)
MA (1) MA41977B1 (fr)
ME (1) ME03414B (fr)
MX (1) MX375737B (fr)
MY (1) MY182382A (fr)
PE (1) PE20180121A1 (fr)
PH (1) PH12017501990B1 (fr)
PL (1) PL3288944T3 (fr)
PT (1) PT3288944T (fr)
RS (1) RS59051B1 (fr)
RU (1) RU2712219C2 (fr)
SG (1) SG11201708822PA (fr)
SI (1) SI3288944T1 (fr)
SM (1) SMT201900393T1 (fr)
TN (1) TN2017000428A1 (fr)
TW (1) TWI695838B (fr)
UA (1) UA123050C2 (fr)
WO (1) WO2016174188A1 (fr)
ZA (1) ZA201706847B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
EP3529250B1 (fr) 2016-10-18 2023-12-06 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones et pyrazolopyridinones en tant qu'inhibiteurs de pde1
WO2018078042A1 (fr) 2016-10-28 2018-05-03 H. Lundbeck A/S Traitements combinés comprenant l'administration d'imidazopyrazinones
HUE050403T2 (hu) 2016-10-28 2020-12-28 H Lundbeck As Imidazopirazinonokkal végzett kombinációs kezelések pszichiátriai és/vagy kognitív betegségek kezelésére
JOP20190126A1 (ar) 2016-12-22 2019-05-28 H Lundbeck As بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1
EP3562828A1 (fr) 2016-12-28 2019-11-06 Dart NeuroScience LLC Composés pyrazolopyrimidinone substitués en tant qu'inhibiteurs de pde2
WO2019104285A1 (fr) 2017-11-27 2019-05-31 Dart Neuroscience, Llc Composés furanopyrimidine substitués utilisés en tant qu'inhibiteurs de pde1
AR113926A1 (es) * 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
CN117447475A (zh) 2017-12-20 2024-01-26 H.隆德贝克有限公司 作为PDE1抑制剂的吡唑并[4,3-b]吡啶和咪唑并[1,5-a]嘧啶
US20210205310A1 (en) 2018-05-25 2021-07-08 Intra-Cellular Therapies, Inc. Organic compounds
IT202200024948A1 (it) * 2022-12-05 2024-06-05 Angelini Pharma S P A Composti attivatori dei canali potassio KV7.2/KV7.3

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB973361A (en) 1960-05-11 1964-10-28 Ciba Ltd Pyrazolo-pyrimidines and process for their manufacture
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
AU2004235915B2 (en) 2003-05-09 2010-08-05 Boehringer Ingelheim International Gmbh 6-cyclylmethyl- and 6-alkylmethyl-substituted pyrazolopyrimidines
ES2652440T3 (es) * 2004-04-02 2018-02-02 OSI Pharmaceuticals, LLC Inhibidores de proteína cinasa heterobicíclicos sustituidos con anillo 6,6-bicíclico
US7872124B2 (en) * 2004-12-21 2011-01-18 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2007025103A2 (fr) * 2005-08-23 2007-03-01 Intra-Cellular Therapies, Inc. Composes organiques
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
JP5837278B2 (ja) 2006-12-05 2015-12-24 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規使用
PT2152712E (pt) 2007-05-11 2012-02-29 Pfizer Compostos amino-heterocíclicos
US20090143391A1 (en) 2007-11-30 2009-06-04 Norbert Hofgen Aryl and heteroaryl fused imidazo [1,5-a] pyrazines as inhibitors of phosphodiesterase 10
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
BRPI0918527A2 (pt) 2008-09-08 2015-12-01 Boehring Ingelheim Internat Gmbh compostos para o tratamento de disturbios do cns
MX2011005934A (es) 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
EA201170768A1 (ru) * 2008-12-06 2012-05-30 Интра-Селлулар Терапиз, Инк. Органические соединения
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
EP2440234A4 (fr) 2009-06-10 2013-11-06 Univ New York Ciblage immunologique de protéines tau pathologiques
US9434730B2 (en) 2010-05-31 2016-09-06 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
PT3042917T (pt) 2010-08-12 2018-05-02 Lilly Co Eli Anticorpos do péptido beta amilóide anti-n3pglu e seus usos
EP3181566A1 (fr) * 2010-09-20 2017-06-21 Ironwood Pharmaceuticals, Inc. Composes imidazotriazinones
EP2619204A4 (fr) 2010-09-21 2014-08-27 Merck Sharp & Dohme Triazolopyrazinones comme antagonistes des récepteurs p2x7
JO3089B1 (ar) 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
US9499610B2 (en) 2011-04-08 2016-11-22 H. Lundbeck A/S Antibodies specific to pyroglutamated Aβ
JP6051210B2 (ja) 2011-06-10 2016-12-27 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
HK1211023A1 (zh) 2011-10-10 2016-05-13 H. Lundbeck A/S 具有咪唑并吡嗪骨架pde9i
HK1199879A1 (en) 2012-01-26 2015-07-24 H.隆德贝克有限公司 Pde9 inhibitors with imidazo triazinone backbone
JP2013166727A (ja) 2012-02-16 2013-08-29 Dainippon Sumitomo Pharma Co Ltd ジヒドロイミダゾピラジノン誘導体
US9499562B2 (en) 2012-06-18 2016-11-22 Dart Neuroscience (Cayman) Ltd. Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds
ES2836129T3 (es) 2013-03-15 2021-06-24 Intra Cellular Therapies Inc Compuestos orgánicos
JP5783297B2 (ja) 2013-08-06 2015-09-24 株式会社デンソー 力学量センサ
AP2016009370A0 (en) 2014-02-19 2016-08-31 H Lundbeck As 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
JP5797815B1 (ja) 2014-06-27 2015-10-21 細田建設株式会社 後施工アンカー及びその施工方法
US20160083391A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic piperazine derivative
US20170273985A1 (en) 2014-09-18 2017-09-28 Sunovion Pharmaceuticals Inc. Tricyclic derivative
US20160083400A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic guanidine derivative
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
MA40941A (fr) 2014-11-10 2017-09-19 H Lundbeck As 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
JO3458B1 (ar) 2014-11-10 2020-07-05 H Lundbeck As 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
CR20170187A (es) 2014-11-10 2018-02-01 H Lundbeck As 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer
US20180044343A1 (en) 2015-03-16 2018-02-15 Sumitomo Dainippon Pharma Co., Ltd. Bicyclic imidazolo derivative
TW201643167A (zh) 2015-04-22 2016-12-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之咪唑並三酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
CA2993630A1 (fr) 2015-08-12 2017-02-16 H. Lundbeck A/S 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridines comme inhibiteurs de bace1
TWI609870B (zh) 2016-02-12 2018-01-01 美國禮來大藥廠 Pde1抑制劑
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
EP3529250B1 (fr) 2016-10-18 2023-12-06 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones et pyrazolopyridinones en tant qu'inhibiteurs de pde1
HUE050403T2 (hu) 2016-10-28 2020-12-28 H Lundbeck As Imidazopirazinonokkal végzett kombinációs kezelések pszichiátriai és/vagy kognitív betegségek kezelésére
WO2018078042A1 (fr) 2016-10-28 2018-05-03 H. Lundbeck A/S Traitements combinés comprenant l'administration d'imidazopyrazinones

Also Published As

Publication number Publication date
ECSP17072228A (es) 2018-02-28
MX375737B (es) 2025-03-06
PE20180121A1 (es) 2018-01-18
US10858362B2 (en) 2020-12-08
TWI695838B (zh) 2020-06-11
HK1252098B (en) 2020-02-07
KR102605759B1 (ko) 2023-11-23
US11472810B2 (en) 2022-10-18
TW201700477A (zh) 2017-01-01
EA031946B1 (ru) 2019-03-29
CA2983563A1 (fr) 2016-11-03
BR112017023182A2 (fr) 2018-10-02
RU2712219C2 (ru) 2020-01-27
JP6663930B2 (ja) 2020-03-13
ME03414B (fr) 2020-01-20
ES2735422T3 (es) 2019-12-18
HUE044244T2 (hu) 2019-10-28
PT3288944T (pt) 2019-07-19
CY1121806T1 (el) 2020-07-31
EP3288944A1 (fr) 2018-03-07
DK3288944T3 (da) 2019-07-22
JO3627B1 (ar) 2020-08-27
HK1252098A1 (en) 2019-05-17
CO2017010399A2 (es) 2018-01-05
US10011606B2 (en) 2018-07-03
UA123050C2 (uk) 2021-02-10
WO2016174188A1 (fr) 2016-11-03
SMT201900393T1 (it) 2019-09-09
MY182382A (en) 2021-01-22
HRP20191180T1 (hr) 2019-10-04
JP2018514552A (ja) 2018-06-07
KR20170140216A (ko) 2017-12-20
ZA201706847B (en) 2019-01-30
BR112017023182B1 (pt) 2023-10-31
SI3288944T1 (sl) 2019-08-30
IL255316A0 (en) 2017-12-31
EA201792157A1 (ru) 2018-03-30
LT3288944T (lt) 2019-07-25
US20160318939A1 (en) 2016-11-03
US20190062335A1 (en) 2019-02-28
PH12017501990B1 (en) 2021-01-13
TN2017000428A1 (en) 2019-04-12
MX2017013785A (es) 2018-03-27
AU2016256573B2 (en) 2019-11-21
RU2017137514A (ru) 2019-05-31
CL2017002719A1 (es) 2018-04-20
PH12017501990A1 (en) 2018-03-26
US20170291903A1 (en) 2017-10-12
AU2016256573A1 (en) 2017-12-14
IL255316B (en) 2021-10-31
EP3288944B1 (fr) 2019-06-12
US20210238182A1 (en) 2021-08-05
GT201700223A (es) 2018-12-19
PL3288944T3 (pl) 2019-11-29
RU2017137514A3 (fr) 2019-07-17
DOP2017000254A (es) 2018-01-15
RS59051B1 (sr) 2019-08-30
CN107531714B (zh) 2019-07-19
SG11201708822PA (en) 2017-11-29
GEP20207058B (en) 2020-01-27
MA41977B1 (fr) 2019-08-30
CN107531714A (zh) 2018-01-02

Similar Documents

Publication Publication Date Title
CY2024003I2 (el) Ενωσεις χρησιμες ως αναστολεις κινασης
MA41977A (fr) Imidazopyrazinones utilisées comme inhibiteurs de pde1
LT3436461T (lt) Pirolotriazino junginiai kaip tam inhibitoriai
IL251420A0 (en) Triazolopyrazinones as pde1 inhibitors
LT3303334T (lt) Tirozinkinazės inhibitoriai
EP3347008A4 (fr) Inhibiteurs de bêta-lactamases
DK3072835T3 (da) Fremgangsmåde til fremføring
EP3313828A4 (fr) Inhibiteurs de métallo-bêta-lactamases
MA41677A (fr) Composés alpha-cinnamide et compositions comme inhibiteurs de hdac8
MA44006A (fr) Inhibiteur pde1
EP3347333C0 (fr) Compositions inhibitrices de polymérisation
EP3334726A4 (fr) Compositions de plinabuline
DK3250182T3 (da) Dispergible sammensætninger
DK3116475T3 (da) Dopa-decarboxylasehæmmersammensætninger
MA42597A (fr) 2-amino-3-fluoro-3-(fluorométhyl)-6-méthyl-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
EP3394068A4 (fr) Inhibiteurs de tdo2
EP2976340A4 (fr) Cycloalkylnitrile pyrazolopyridones utilisées comme inhibiteurs de la janus kinase
DK3717488T3 (da) Substituerede furanopyrimidinforbindelser som pde1-inhibitorer
DK3331498T3 (da) Nasalsammensætning
DK3316857T3 (da) Multifasiske sammensætninger
EP3302486A4 (fr) Composés de dihydropyrazolopyrimidinone utilisés comme inhibiteurs de pde2
LT3126354T (lt) Halogeninti kvinazolin-thf-aminai kaip pde1 inhibitoriai
IL246718A0 (en) Hexahydrofuropyrroles as pde1 inhibitors
EP3414334C0 (fr) Procédé